拼接因子激酶SRPK1是对周围血管疾病的治疗点
Sohni Ria Bhalla1, Mussarat Wahid1, Jason O Amartey1
1Division of Cancer and Stem Cells, Tumour and Vascular Biology Laboratories, Centre for Cancer Sciences, School of Medicine, Biodiscovery Institute, University of Nottingham, Nottingham, United Kingdom.
概括
在外围动脉疾病 (PAD) 中,抑制单细胞中的SRPK1激酶可以防止抗血管原VEGF-A165b拼接. 这促进了血管生长,并在临床前模型和人体细胞研究中改善了血液循环.
科学领域:
- 分子生物学分子生物学
- 心血管研究研究心血管研究
- 血管新生的产生.
背景情况:
- 单细胞中抗血管原体VEGF-A165b异型的过度表达有助于在周围动脉疾病 (PAD) 中降低附带的功能.
- 氨酸-氨酸蛋白激酶-1 (SRPK1) 是VEGF剪接的一个关键调节器.
- 对于SRPK1在控制单细胞VEGF拼接中的作用及其对PAD抵押的影响仍未完全阐明.
研究的目的:
- 调查SRPK1是否控制单细胞VEGF拼接,从而损害PAD中的担保.
- 评估SRPK1抑制在PAD小鼠模型和人类单细胞中的治疗潜力.
主要方法:
- 在PAD的小鼠模型 (Sfrp5-/-,LysM-Wnt5aGOF,肥胖的HF/HS饮食) 中研究了SRPK1抑制和单细胞特异性淘汰.
- 进行了大腿关节动脉绑定手术,随后接受了SRPK1抑制剂的治疗.
- 创建了一个单细胞特异的SRPK1条件淘汰小鼠模型 (LysM-Cre;SRPK1(LoxP/LoxP)) 并使用激光光斑成像评估血流恢复.
主要成果:
- 在人类PAD单细胞中,SRPK1抑制将VEGF拼接从VEGF-A165b切换到VEGF-A165a,增强内皮细胞迁移.
- 在Sfrp5-/-,LysM-Wnt5aGOF和肥胖的HF/HS小鼠模型中,SRPK1抑制改善了血流恢复.
- 单细胞特异性SRPK1淘汰在LysM-Wnt5aGOF和肥胖小鼠中挽救了受损的重血管化,与向M2巨细胞的转变有关.
结论:
- 抑制SRPK1增强了小鼠模型和PAD体外人类单细胞血管生成模型中的附带担保.
- 与上皮细胞或癌细胞相比,单细胞VEGF拼接的调节方式不同,这表明细胞类型特定的拼接控制.
- 抑制SRPK1代表了通过促进血管生成和改善血液流动来治疗PAD的新治疗策略.
相关概念视频
Alternative RNA Splicing
21.7K
Alternative RNA splicing is the regulated splicing of exons and introns to produce different mature mRNAs from a single pre-mRNA. Unlike in constitutive splicing where a single gene produces a single type of mRNA, alternative splicing allows an organism to produce multiple proteins from a single gene and plays an important role in protein diversity.
There are five types of alternative RNA splicing that vary in the ways the pre-mRNA segments are removed or retained in the mature mRNA. The first...
There are five types of alternative RNA splicing that vary in the ways the pre-mRNA segments are removed or retained in the mature mRNA. The first...
21.7K
RNA Splicing
57.1K
Splicing is the process by which eukaryotic RNA is edited before its translation into protein. The RNA strand transcribed from eukaryotic DNA is called the primary transcript. The primary transcripts that become mRNAs are called precursor messenger RNAs (pre-mRNAs). Eukaryotic pre-mRNA contains alternating sequences of exons and introns. Exons are nucleotide sequences that code for proteins, whereas introns are the non-coding regions. In RNA splicing, introns are removed and exons are bonded...
57.1K
Peripheral Artery Disease I: Introduction
35
Peripheral artery disease (PAD) predominantly results from atherosclerosis, which involves the accumulation of fatty deposits, or plaques, within the walls of arteries. This causes them to narrow and harden, significantly reducing blood flow. PAD predominantly affects the legs, particularly the arteries supplying the thighs and calves. In rare cases, it may involve other arteries, including those in the arms.Etiology of PAD:The principal cause of PAD is atherosclerosis, which results from fatty...
35
PI3K/mTOR/AKT Signaling Pathway
4.0K
The mammalian target of rapamycin (mTOR) is a serine/threonine kinase that regulates growth, proliferation, and cell survival in response to hormones, growth factors, or nutrient availability. This kinase exists in two structurally and functionally distinct forms: mTOR complex 1 (mTORC1) and mTOR complex 2 (mTORC2). The first form (mTORC1) is composed of a rapamycin-sensitive Raptor and proline-rich Akt substrate, PRAS40. In contrast, mTORC2 consists of a...
4.0K
The JAK-STAT Signaling Pathway
9.3K
Several cytokine receptors have tightly bound Janus kinase or JAK proteins attached at their cytosolic tail. Small signaling molecules such as cytokines, growth hormones, or prolactins bind to the cytokine receptors and initiate their dimerization. The dimerization brings the cytosolic JAKs together that trans-phosphorylate and activates each other. The activated JAKs now phosphorylate cytosolic tails of the cytokine receptors, which serve as binding sites for adaptor proteins such as SH2...
9.3K
Peripheral Artery Disease III: Interprofessional Care
33
Peripheral Artery Disease (PAD) is characterized by narrowed arteries that diminish blood flow to the extremities. Effective management of PAD requires an interprofessional approach involving various healthcare professionals. The critical aspects of interprofessional care for PAD patients focus on risk factor modification, drug therapy, exercise therapy, nutrition therapy, critical limb ischemia care, and interventional radiology and surgical procedures.The primary treatment goal for PAD...
33


